Comparison of outcomes between the 2 arms
| . | HD-DXM (n = 95) . | PDN (n = 97) . | P . | OR . | 95% CI . |
|---|---|---|---|---|---|
| Overall response, n (%) | 78 (82.1) | 67 (69.1) | .044 | 2.054 | 1.042-4.050 |
| CR, n (%) | 48 (50.5) | 26 (26.8) | .001 | 2.789 | 1.526-5.097 |
| Median TTR, d (range) | 3 (1-9) | 6 (2-24) | <.001 | ||
| SR, n (%) | 38 (40.0) | 40 (41.2) | .884 | 0.950 | 0.534-1.690 |
| Sustained CR, n (%) | 26 (27.4) | 17 (17.5) | .120 | 1.773 | 0.889-3.539 |
| Additional therapy*, n | |||||
| HD-MP | 2 | 3 | |||
| IVIg | 15 | 14 | |||
| Splenectomy | 5 | 8 | |||
| Rituximab | 12 | 11 | |||
| Rh-TPO | 9 | 8 | |||
| Vincristine | 5 | 4 | |||
| Ciclosporin | 4 | 4 | |||
| Azathioprine | 5 | 3 | |||
| Herbs | 0 | 2 |
| . | HD-DXM (n = 95) . | PDN (n = 97) . | P . | OR . | 95% CI . |
|---|---|---|---|---|---|
| Overall response, n (%) | 78 (82.1) | 67 (69.1) | .044 | 2.054 | 1.042-4.050 |
| CR, n (%) | 48 (50.5) | 26 (26.8) | .001 | 2.789 | 1.526-5.097 |
| Median TTR, d (range) | 3 (1-9) | 6 (2-24) | <.001 | ||
| SR, n (%) | 38 (40.0) | 40 (41.2) | .884 | 0.950 | 0.534-1.690 |
| Sustained CR, n (%) | 26 (27.4) | 17 (17.5) | .120 | 1.773 | 0.889-3.539 |
| Additional therapy*, n | |||||
| HD-MP | 2 | 3 | |||
| IVIg | 15 | 14 | |||
| Splenectomy | 5 | 8 | |||
| Rituximab | 12 | 11 | |||
| Rh-TPO | 9 | 8 | |||
| Vincristine | 5 | 4 | |||
| Ciclosporin | 4 | 4 | |||
| Azathioprine | 5 | 3 | |||
| Herbs | 0 | 2 |
IVIg, intravenous immunoglobulin; PDN, prednisone; Rh-TPO, recombinant human thrombopoietin; TTR, time to response.
These data included ITP-modifying additional therapy administered to initial nonresponders and patients who failed to achieve sustained response.